PharmAbcine Inc. announced that the Company has entered into a clinical collaboration agreement with MSD (Merck & Co. Inc., Rahway, NJ., USA), to initiate a Phase I combination trial of PMC-309, a novel anti-VISTA (V-domain Ig suppressor of T cell activation) antibody, in combination with KEYTRUDA(R) (pembrolizumab), MSD's anti-PD-1 therapy. Under the terms of the agreement, PharmAbcine will sponsor a Phase I study in Australia to evaluate the safety and clinical efficacy of the combination therapy for the treatment of multiple advanced solid tumors, and MSD will supply KEYTRUDA.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
2,915 KRW | -8.91% | -.--% | -22.27% |
1st Jan change | Capi. | |
---|---|---|
-22.27% | 63.64M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- A208340 Stock
- News PharmAbcine Inc.
- Pharmabcine Announces Collaboration Agreement with MSD to Evaluate Anti-Vista Antibody PMC-309 in Combination with Keytruda(R) (Pembrolizumab)